(NASDAQ: PHAT) Phathom Pharmaceuticals's forecast annual revenue growth rate of 51.13% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.02%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Phathom Pharmaceuticals's revenue in 2025 is $147,190,000.On average, 11 Wall Street analysts forecast PHAT's revenue for 2025 to be $12,522,499,593, with the lowest PHAT revenue forecast at $11,572,801,419, and the highest PHAT revenue forecast at $13,036,830,514. On average, 11 Wall Street analysts forecast PHAT's revenue for 2026 to be $23,089,403,471, with the lowest PHAT revenue forecast at $20,217,544,648, and the highest PHAT revenue forecast at $24,948,250,908.
In 2027, PHAT is forecast to generate $36,686,804,892 in revenue, with the lowest revenue forecast at $31,909,147,262 and the highest revenue forecast at $39,843,217,475.